Galecto (GLTO)

• Market cap: $3.75M
• 1 day: -1.39%
• 5 days: 6.79%
• 1 month: -16.27%
• 3 months: -14.76%
• 6 months: -30.64%
• Year to date: -50.35%
• 1 year: -77.82%
• 5 years: -99.25%
• 10 years: -99.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Employees: 5

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2% more capital invested

Capital invested by funds: $442K [Q1] → $451K (+$9.19K) [Q2]

0.77% less ownership

Funds ownership: 10.81% [Q1] → 10.04% (-0.77%) [Q2]

18% less funds holding

Funds holding: 11 [Q1] → 9 (-2) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2